101-PGC-005 for the Treatment of COVID-19

PHASE2UnknownINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

January 31, 2023

Primary Completion Date

April 21, 2023

Study Completion Date

June 30, 2023

Conditions
COVID-19
Interventions
DRUG

101-PGC-005

'005 is a targeted prodrug of dexamethasone that binds to activated macrophages.

DRUG

Dexamethasone

Dexamethasone is a glucocorticoid commonly prescribed to treat inflammation.

Trial Locations (5)

Unknown

Government Medical College & General Hospital, Srikakulam

Victoria Hospital Bangalore, Bangalore

Sangvi Multispeciality Hospital, Pune

SMS Medical College and Attached Hospitals, Jaipur

Santosh Medical College and Hospital, Ghaziabad

Sponsors

Lead Sponsor

All Listed Sponsors
lead

101 Therapeutics

INDUSTRY